Page 193 - PRECONGRESS COURSE 06

S
S
t
ti
i
m
m
u
u
l
l
a
a
t
t
i
io
o
n
n
o
of
fc
co
or
rp
p
o
o
r
ra
a
l
l
u
ut
te
ea
a
a
af
ft
te
er
rG
G
n
n
R
RH
Ha
ag
g
o
o
n
ni
i
s
s
t
tt
t
r
ri
i
g
g
g
g
e
er
ri
in
n
g
g
D
D
u
ua
a
l
l
t
t
r
r
i
i
g
g
g
g
e
er
ri
i
n
n
g
go
of
ff
f
i
in
n
a
al
l
o
oo
oc
cy
y
t
t
e
e
m
m
a
at
t
u
u
r
r
a
at
ti
io
on
n
w
wi
it
t
h
ht
th
he
ec
co
o
m
mb
b
i
in
n
a
at
ti
i
o
o
n
no
o
f
f
G
Gn
n
R
R
H
Ha
ag
g
o
o
n
n
i
is
st
ta
an
n
d
d
h
hC
CG
G
Only retrospective studies available
D
D
u
ua
a
l
l
t
t
r
r
i
i
g
g
g
g
e
er
ri
i
n
n
g
go
of
ff
f
i
in
n
a
al
l
o
oo
oc
cy
y
t
t
e
e
m
m
a
at
t
u
u
r
r
a
at
ti
io
on
n
w
wi
it
t
h
ht
th
he
ec
co
o
m
mb
b
i
in
n
a
at
ti
i
o
o
n
no
o
f
f
G
Gn
n
R
R
H
Ha
ag
g
o
o
n
n
i
is
st
ta
an
n
d
d
h
hC
CG
G
Lin et al 2013
Population
hCG dose
Dual triggering
hCG
Luteal support
Low risk
Normal dose
250μG rec hCG +0.2 mg of triptorelin
250μG rec hCG
50 mg IM P 300 mg vag P
n
191
187
LBR
41.36 34.3 – 48.7
30.49 23.9 – 37.6
OHSS
0
0 – 1.9
0 0 -2
Griffin et al 2012
Population
hCG dose
Dual triggering
Agonist triggering
Luteal support
High risk
Low dose
1,000 IU hCG +
1 mg leuprolide acetate
1 mg leuprolide acetate
50mg IMP(MAX 75mg)
0.3 mg E2 TDS (max 0.4mg and or 2mg/PO)
n
34
68
LBR
52.9 35.1 - 70.2
30.9 20.2 – 43.2
OHSS
0
0
Shapiro et al 2008
Population
hCG dose
0 – 10.2
Dual triggering
0- 10.4
Luteal support
High risk
Low dose
4 mg of leuprolide acetate + 1000-2000 IU hCG
E2 ,P
n
45
OPR
53.3 % 37.8 to 68.3
OHSS
0
Page 189 of 258
PRECONGRESS COURSE 06 I GENEVA, SWITZERLAND – 2 JULY 2017 193